| Open Trial |
Description |
NCIC Protocol number
IND. 138 |
Randomized Phase II study of NX 211 given by two different intravenous schedules in advanced and/or recurrent epithelial ovarian cancer |
NCIC Protocol number
OV 13 EORTC 55971 |
Randomized Phase III study comparing upfront debulking surgery versus neoadjuvant chemotherapy in patients with Stage IIIC or IV epithelial ovarian cancer |
NCIC Protocol Number
OV 14 EORTC 55981 |
Randomized Phase III study of paclitaxel/epirubicin/carboplatinum (TEC) versus paclitaxel/carboplatinum (TC) in the treatment of patients with advanced ovarian cancer |
| OVA-Gy-15 |
A multicentre clinical trial of intravenous OvaRexTM Mab-B43.13 as post chemotherapy consolidation for ovarian. Tubal and peritoneal carcinoma. |
| PALO-99-04 |
A double-blind clinical trial to compare single IV doses of palonestron, 0.25 mg or 0.75 mg. and dolasetron, 100 mg IV, in the prevention of moderately emetogenic chemotherapy-induced nausea and vomiting. |
| PALO-99-05 |
A double-blind clinical trail to compare single IV doses of palonosetron, 0.25 mg or 0.75 mg. and ondansetron, 32 mg. IV, in the prevention of highly emetogenic chemotherapy-induced nausea and vomiting |
| PALO-99-06 |
A mulicenter, open-label study to assess the safety and efficacy of IV palonosetron for the prevention of chemotherapy-induced nausea and vomiting in repeated chemotherapy cycles. |
